OKLAHOMA CITY , Sept. 24, 2024 /PRNewswire/ -- Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today an expansion in capabilities through the licensing of ATUM's innovative miFucTM platform designed for expression of recombinant proteins containing afucosylated glycans.
ATUM's miFucTM technology is the industry-leading platform for the development of antibodies with significant reduction in fucosylation without affecting product titer, cellular growth rates, or incurring global glycan liabilities. Enabled by ATUM's proprietary Leap-In Transposase ® technology, antibodies produced using miFucTM embedded expression vectors exhibit significantly increased antibody-dependent cellular cytotoxicity (ADCC), resulting in improved efficacy for select therapeutics. This license agreement allows Wheeler Bio's clients the option to produce therapeutic antibodies with greater effector engagement and antibody-dependent cellular cytotoxicity for increased therapeutic windows with reduced toxicity.
Wheeler Bio previously integrated ATUM's VectorGPS ® design platform, Leap-In Transposase ® technology, and miCHOTM host cell line with Wheeler's Portable CMC ® process platform to deliver a predictable, reliable, and scalable process for accelerating antibodies from discovery into clinical manufacturing. This additional licensing agreement with ATUM further expands Wheeler Bio's antibody platform capabilities by facilitating the production of .